Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243202 · ClinicalTrials.gov registry record · Phase 2
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
A Phase 2 study of Obesity, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 335
- Enrollment target
- 17
- Study locations
NCT02243202: Completed Phase 2 study of Obesity, sponsored by Janssen Research & Development.
NCT02243202 is a Phase 2 study of Obesity that has completed, run by Janssen Research & Development. The registered enrollment target is 335 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243202, a Phase 2 study of Obesity, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 335 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
Primary Outcome
The percent change from baseline in body weight at Week 26 was analysed.
Conditions Studied
Interventions
- DRUG Phentermine
- DRUG Canagliflozin
- DRUG Matching Placebo to Canagliflozin
- DRUG Matching Placebo to Phentermine
Study Locations (17)
Kentucky
- - Lexington
- - Louisville
Texas
- - Dallas
- - Odessa
Arizona
- - Phoenix
California
- - Walnut Creek
Florida
- - Jacksonville
Idaho
- - Meridian
Indiana
- - Evansville
Louisiana
- - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT02243202 record still lists
NCT02243202 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Phentermine is the first listed.
NCT02243202 lists 17 locations in 15 states (Kentucky, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT02243202 about?
NCT02243202 is a clinical study titled "Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants". The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
What is the current status of trial NCT02243202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 335 participants. The study started on 2014-09. Estimated completion is 2015-06.
What conditions does trial NCT02243202 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT02243202?
The interventions under investigation include: Phentermine (DRUG), Canagliflozin (DRUG), Matching Placebo to Canagliflozin (DRUG), Matching Placebo to Phentermine (DRUG).
Who is sponsoring clinical trial NCT02243202?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243202 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02243202's enrollment target sits among peer trials
335 200th of 1053 higher than 854 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia